A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer

Abstract De-escalating adjuvant therapy following pathologic complete response (pCR) to an abbreviated neoadjuvant regimen in human epidermal growth factor receptor 2-positive (HER2+) breast cancer is the focus of international research efforts. However, the feasibility of this approach and its appe...

詳細記述

保存先:
書誌詳細
主要な著者: Adrienne G. Waks, Neelam V. Desai, Tianyu Li, Philip D. Poorvu, Ann H. Partridge, Natalie Sinclair, Laura M. Spring, Meredith Faggen, Michael Constantine, Otto Metzger, Jillian Alberti, Julia Deane, Shoshana M. Rosenberg, Elizabeth Frank, Sara M. Tolaney, Ian E. Krop, Nadine M. Tung, Nabihah Tayob, Tari A. King, Elizabeth A. Mittendorf, Eric P. Winer
フォーマット: Artigo
言語:Inglês
出版事項: Nature Portfolio 2022-05-01
シリーズ:npj Breast Cancer
オンライン･アクセス:https://doi.org/10.1038/s41523-022-00429-7
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料